Six Years, One Forged Prescription, and the Marathon Silence No Camera Captured

Whenever I have stood on that empty track in Patiala over the last few years, one thing has always struck me — a stadium's silence is never alone. It has a chorus too; it just demands the listener's patience. That habit of listening to silence taught me that the biggest story in sport is often hidden in the moment no graphic or replay captures. Reading about Ruti Aga's six-year ban brought that feeling back. The headlines carry a marathon runner and a forged prescription. But the real story lies behind the document — a knee injury, a clinic that did not exist, and a family member who called himself a doctor. According to the Athletics Integrity Unit (AIU) statement, the case stems from a half marathon won in China in March, where the sample collected tested positive. Stay with me, because I want to take you to the part that separates this from a routine doping story. For me, this is not merely a sanction report. It is a document of the governance failure lived daily inside East African road-running entourages, where a medical support system often stands as an uncertain shadow behind the medal's shine.

Let us step back. Ruti Aga is an Ethiopian marathoner, 32 years old, with the 2026 Tokyo Marathon title to her name and three second-place finishes at World Marathon Majors. My source does not provide her personal best, but external records (still pending verification) place her at roughly 2:18:34 in Berlin 2026 and 2:20:40 in Tokyo 2026. It is important to understand that Ethiopian and Kenyan depth in the women's marathon is so extreme that even a 2:18-class runner cannot feel secure about national selection. When an athlete loses rhythm to injury, the pressure to protect both appearance-fee income and career arrives at once. That is where the decision begins that later turns into a six-year ban. According to the source, her sample came back positive after that March half marathon in China. It would have been a World Athletics Label road race, with an elite women's field and in-competition testing. I should also make clear that her time, splits, or the strength of the field from that race are not in the source, so I do not permit myself any comment on the performance. The only performance-relevant fact for me is that she won it, which implies an elite field and a testing apparatus were present.

Now comes the part where the technical knot of this story opens. The media report calls the substance a 'prohibited steroid' and claims WADA classifies it as performance-enhancing. I will be very clear here because, for me, precision of words is not a dictionary matter but a matter of provisions. Methylprednisolone is a glucocorticoid, falling under Class S9 of the WADA Prohibited List. It is not an anabolic steroid (Class S1). Under the current List, S9 glucocorticoids are prohibited only in-competition, and only by injection, oral, or rectal routes. The direct implication is that a therapeutic knee injection is entirely legal out-of-competition and becomes a violation only if residues are present in-competition. The case here was not about 'steroid use' but about 'timing and route.' In my nine years of observation, I have seen many athletes assume that getting treatment is enough, when the real game is about timing and documentation. In Aga's case, a legitimate defence pathway existed — had she produced genuine medical records, correct timing, and the proper administrative route. What happened was the opposite. According to the source, a prescription was submitted citing treatment for the injury, which the AIU found to be forged in its investigation. The clinic named on the prescription did not exist; the person who wrote it as a 'doctor' was a family member with no medical registration; and he claimed to have used 'an old prescription pad from a former workplace,' which the clinic explicitly disowned. These are three independent verification failures, and that is precisely the hardest evidence in this case. If the treatment had genuinely occurred and records existed, there would have been no need to forge a prescription.

Now understand the arithmetic of the sanction, because the real technical story lives here. According to the source, a two-year ban has been imposed for the presence violation, which typically happens when the substance falls into the 'Specified Substance' category and intent is not proven. On top of that, a four-year ban has been added for tampering, which is the standard sanction under the Code. Two plus four equals six. Both are dated from 10 September, the same date she was provisionally suspended. One thing is clear from this arithmetic — the panel rejected the 'no significant fault' mitigation that ordinarily reduces a presence sanction. For me, this ban is effectively career-ending. Add six years to age 32, and the return would come at roughly 38. Given the depth of Ethiopian women's marathon running, a 38-year-old with a doping record is practically locked out of national selection. One more technical point — the backdating to 10 September is no concession. Time served in provisional suspension counts against the ban, so the athlete gains nothing in real terms.

Here I must turn to the angle that should be debated but probably will not be. The way the source uses the word 'steroid' casts the whole case in the wrong mould. Methylprednisolone is not an anabolic steroid but a glucocorticoid, which has no proven performance-enhancing benefit in endurance sport. Yet a six-year ban has been imposed for a substance with no proven benefit, and that is the greatest paradox of this case. In my experience with East African road-racing cases handled by the AIU, a pattern emerges — first a substance violation, then an attempt to conceal it, then a tampering sanction. This case belongs to that family. The question is not whether the sanction is strict; the question is whether that strictness lands where it is needed. If you ask me, my concern is less about the athlete and more about the system that left her so alone that a family member sat down to write a prescription as a 'doctor.' I am not, under any circumstance, calling the forgery right. Forgery destroys the defence pathway itself. But this case shows criminality and administrative weakness side by side, and arguing only over the two-year presence sanction achieves nothing.

Now comes the detail most overlooked — nutrition and entourage. The source does not say whether Aga had a credentialed team physician, but the manner in which the prescription was produced suggests medical support was either informal or absent. An athlete with a Therapeutic Use Exemption (TUE) framework keeps records of injury treatment and waits out the correct washout period if she needs to compete. Neither appears to have happened here. I want to add something I have observed on my field trips. When I stood in the stands at tracks like Patiala's, I knew these athletes did not have a full physio staff. There was a coach, a bag, and trust. When a marathoner returns home with knee pain, she often has a circle of 'trusted' people who are not doctors but still give advice. When that circle produces a document, it becomes forgery in the legal sense. My understanding is that this is the real temptation in this case — not treatment, but the appearance of treatment. And that appearance arises when an athlete comes to believe the system will not help her.

I also want to say that as China's half marathon circuit increasingly becomes a major source of appearance fees for these elite athletes, the AIU's gaze there is now sharpest. It is no coincidence that a runner races in China in March and then faces a ban in September. There is big money in these races, a large pool of elite athletes, and equally dense testing. For me, this is a crossroads where appearance-fee and testing-fee collide in the same race. The result of this collision will be more cases like this in the coming years. This is my prediction, and I offer a receipt with it: in East African road-running camps where a single medical network serves many athletes, one case surfacing means more are in the pipeline.

Now I must return to the question that troubles me most — is this sanction severe, or is it unequal? When you impose a six-year ban for glucocorticoid use, you are imposing the heaviest sanction for a substance with no proven performance benefit in endurance. Conversely, in sprint and power events, anabolic steroid cases often draw lighter sanctions. I am not saying Aga should be acquitted. I am saying there must be a universal language of justice, and it should be determined by the power of the substance, not by the document that came with it. For me, this case is as much about the system that leaves an athlete alone as it is about forgery. A 32-year-old runner holds the 2026 Tokyo title and three Major podiums. Those will remain the brightest pages of her career. But now, when she contemplates a return at nearly 38, she will face the depth of Ethiopian running where even 2:18 performers fall off the line.

And here I leave a question of my own. When Ruti Aga returns after six years, will she be welcomed in a stadium, or only on an empty track and in that same silence? In 2026, at that deserted stadium in Patiala, I watched a 17-year-old middle-distance runner from Kerala, P.M. Anjali, run, and at that moment only her breath and footsteps were audible. That day I realised silence has its own voice. In Aga's case, that silence is now the voice of a forged document, speaking louder than the system that allowed it to be created. And until we confine that voice to a single guilty athlete, the next prescription will keep being written somewhere else.